Arcutis Biotherapeutics (ARQT) Quarterly Loss After Q4 Profit Tests Bullish Profitability Narrative

Arcutis Biotherapeutics (ARQT) opened 2026 with Q1 revenue of US$105.4 million and a basic EPS loss of US$0.09, as net income excluding extra items came in at a loss of US$11.3 million. The company has seen quarterly revenue move from US$71.4 million in Q4 2024 to US$65.8 million in Q1 2025, then to US$81.5 million, US$99.2 million and US$129.5 million through the rest of 2025 before the latest Q1 2026 figure. Over that stretch, EPS ranged from a loss of US$0.20 in Q1 2025 to a profit of US$0.14 in Q4 2025 and then back to a loss this quarter, creating a closely watched story on how margins are evolving.

See our full analysis for Arcutis Biotherapeutics.

With the headline numbers on the table, the next step is to weigh them against the big-picture narratives around Arcutis Biotherapeutics to see which stories about growth, profitability and risk still hold up and which look out of sync with the latest results.

See what the community is saying about Arcutis Biotherapeutics

Trailing losses narrow to US$2.4 million

• On a trailing 12 month basis to Q1 2026, Arcutis Biotherapeutics booked total revenue of US$415.6 million and a net loss excluding extra items of US$2.4 million, compared with a trailing loss of US$16.1 million on US$376.1 million of revenue one quarter earlier.
• Analysts' bullish view that earnings could grow about 49.1% per year and move into profitability within three years leans heavily on this pattern of shrinking trailing losses. However, Q1 2026 still came in at a loss of US$11.3 million after a profitable Q4 2025, so investors are relying on forecasts rather than a clean, unbroken run of profitable quarters.
  • Revenue over the trailing 12 months has risen from US$196.5 million at Q4 2024 to US$415.6 million at Q1 2026, which lines up with bullish expectations of revenue growth around 18.9% per year.
  • At the same time, trailing net losses have moved from US$140.0 million to US$2.4 million, which strongly supports the bullish claim that losses have been reduced at about 18.3% a year over five years. The return to a quarterly loss in Q1 2026, however, shows that path is not yet smooth.

Some investors will want to see how this earnings path fits into the wider bullish thesis around future growth and margins before making up their mind about the stock's risk and reward profile. 🐂 Arcutis Biotherapeutics Bull Case

Valuation gap vs forecasts

• With the stock at US$20.66, analysts point to a price target of US$34.63 and a DCF fair value of about US$81.45, while the current P/S of 6.2x sits below both the 10.9x industry average and 8.9x peer average.
• What stands out for the bullish camp is how these valuation markers line up with the growth forecasts. The spread between the current share price and the higher numbers also means investors are assuming that projected revenue growth of roughly 18.9% a year and margin expansion from about a 4.3% loss today to 33.9% in three years will play out as expected.
  • Revenue would need to reach around US$784.6 million and earnings about US$266.1 million by 2029 for analysts' price target to be met on their assumed P/E of 22.5x, which is above the current 17.1x P/E cited for the wider US biotechs industry.
  • The stock is also described as trading roughly 74.6% below the DCF fair value estimate, so the bullish narrative is closely tied to the idea that the market is applying a large discount to those long range growth and profitability assumptions.

Current unprofitability and insider selling

• Even with the trailing 12 month loss trimmed to US$2.4 million, Arcutis Biotherapeutics remains unprofitable and recent data flags significant insider selling over the past three months.
• Bears focus on the combination of ongoing operating losses and that insider selling, arguing it pushes against the optimistic revenue and margin trajectory. The gap between the current share price of US$20.66 and the US$34.63 analyst target can also look less compelling if earnings do not track the forecast path.
  • Quarterly results still swing from a profit of US$17.4 million in Q4 2025 back to a loss of US$11.3 million in Q1 2026, which backs the bearish concern that profitability is not yet established.
  • The company’s reliance on a single main product and the limited internal pipeline, alongside the insider selling signal, are central to the bearish narrative that projected growth and margin gains may be harder to achieve than the forecasts suggest.

If you want to see how these risk signals stack up against the cautious view on future earnings and product concentration, it is worth checking the full bear case narrative. 🐻 Arcutis Biotherapeutics Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Arcutis Biotherapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

The mix of risks and rewards in this story is clear. This may be a good time to review the numbers yourself, stress test the narratives, and see the 5 key rewards and 1 important warning sign

Explore Alternatives

Arcutis Biotherapeutics is still posting quarterly losses, facing profitability swings and insider selling, which together raise questions about earnings stability and overall risk.

If you want ideas that put stability and downside protection first, check out the 72 resilient stocks with low risk scores to compare companies with more resilient risk profiles today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com